Despite their benefits, new therapies for respiratory syncytial virus (RSV) may accelerate the emergence of drug-resistant strains, according to a new report on Monday.Given the large market potential and high unmet need for new RSV therapies, .
New York, March 13 (IANS) Despite their benefits, new therapies for respiratory syncytial virus (RSV) may accelerate the emergence of drug-resistant strains,
New RSV therapies may drive emergence of drug-resistant strains: Report webindia123.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webindia123.com Daily Mail and Mail on Sunday newspapers.
Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory tract infections worldwide, recently there has been a surge in interest in RSV antigens, antibodies, and more in therapeutic and immunological development.
Nirsevimab significantly protected infants against RSV disease in Phase III MELODY trial astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.